NCT00478374已完成1 期
Transarterial Chemoembolisation With Doxorubicin in Combination With Systemic Administration of Sorafenib for Patients With Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- To assess the safety and tolerability of the administration of sorafenib in patients with hepatocellular carcinoma treated with TACE by determining the MTD.
研究概览
简要总结
The purpose of this study is to determine the feasibility to combine sorafenib with transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The hypothesis is that sorafenib may prevent the development and growth of tumoral lesions not treated by chemoembolisation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with inoperable HCC, who are candidates for transarterial chemoembolization (TACE).
- •Diagnosis of hepatocellular carcinoma based on the EASL's criteria (1).
- •Child-Pugh score < 10 (Child A or B),
- •Life expectancy superior to 12 weeks at the pre-treatment evaluation.
- •Local therapies have been interrupted for at least 4 weeks
- •Written informed consent signed
- •Age >= 18
- •Performance status ECOG 0-1
- •Normal organ and marrow function defined as:
- •Haematopoietic: absolute neutrophil count >1,500/mm3, platelet count > 60,000/mm3, haemoglobin > 9g/dL
- •INR < 1.5 ULN and PTT within normal limits
- •Hepatic: AST or ALT < 5 x ULN
- •Renal: creatinine < 1.5 x ULN
- •Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
- •Women of childbearing potential and men must agree to use adequate birth contraception (must be double and methods recorded) prior to study entry and for the duration of the study participation. For both men and women, these adequate birth control measures must be used for at least 3 months after the last administration of study drug.
排除标准
- •Active heart disease is defined as congestive heart failure >NYHA (New York Heart Association) class 2; active coronary artery disease (myocardial infarction more than 6 months prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted) or uncontrolled hypertension.
- •Congestive heart failure, serious cardiac arrhythmia, active coronary artery disease.
- •Thrombotic or embolic events within the past 6 months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.
- •Psychiatric illness/social situations that would limit compliance with study requirements.
- •Patients with evidence of active infection will become eligible for reconsideration 7 days after completing antibiotic therapy.
- •HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib.
- •Patients who have been treated with sorafenib.
- •Cerebral metastasis.
- •Child-Pugh score C.
- •Hypertension defined as systolic blood pressure greater than 150 mmHg or diastolic pressure greater than 90 mmHg despite optimal medical management.
- •Proteinuria defined as a 24-hour urine protein excretion greater than 1000 mg. Urine dipstick proteinuria of 1+ or greater will require a 24-hour urine to determine eligibility for enrolment.
- •Therapeutic anticoagulation with coumarin, heparins, or heparinoids.
- •Serious non-healing wounds (including wounds healing by secondary intention), acute or non-healing ulcers, or bone fractures within 3 months of fracture.
- •Evidence of bleeding diathesis.
- •Impairment of swallowing that would preclude administration of sorafenib.
- •History of haemoptysis or surgery within the past 28 days.
- •Organ allograft.
- •Pregnant or breastfeeding patients.
研究组 & 干预措施
1
Experimental
干预措施: Sorafenib (Drug)
1
Experimental
干预措施: Transarterial chemoembolisation with doxorubicin (Procedure)
结局指标
主要结局
To assess the safety and tolerability of the administration of sorafenib in patients with hepatocellular carcinoma treated with TACE by determining the MTD.
时间窗: 2 years
次要结局
- tumor volumetry(2 years)
- changes in the blood concentration of tumor marker AFP(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From MelanomaStage IV MelanomaNCT01010984Robert C. Martin20
终止
2 期
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCCCarcinoma, HepatocellularNCT00576056University of Pittsburgh19
已完成
2 期
Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular InvasionHepatocellular CarcinomaNCT01901692Asan Medical Center90
Unknown
3 期
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCCHepatocellular CarcinomaNCT04143191Sun Yat-sen University158
已完成
3 期
Sorafenib Chemoembolization Evaluation Controlled TrialHepatocellular CarcinomaNCT01906216Air Force Military Medical University, China199